In light of the recent FDA approval of the first Bcl-2 inhibitor, Venetoclax (ABT-199), for patients with chronic lymphocytic leukemia with the 17p deletion, as well as the encouraging phase I-III clinical trials in development for Venetoclax as a monotherapy and/or combination therapy for various types of cancer [70], our capability to accurately predict the treatment outcome of a targeted intervention within the apoptosis signaling cascade is a particularly pertinent finding. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.